Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 4/20 | 0.38 |
| ▸ | PREP | P48147 | 3/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.33 |
| ▸ | FEN1 | P39748 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16223358 | 0.81 | CA12 (0.40) | CA12CA1CA9PREPALOX5AP | |
| SCHEMBL25627212 | 0.81 | CA12 (0.37) | CA12CA1CA9PREPALOX5AP | |
| SCHEMBL1727022 | 0.78 | CA12 (0.41) | CA12CA1CA9PREPALOX5AP | |
| SCHEMBL17318153 | 0.74 | CA12 (0.47) | CA12CA1CA9PREPALOX5AP | |
| SCHEMBL6763899 | 0.74 | PREP (0.53) | CA12CA1CA9PREPALOX5AP | |
| SCHEMBL2641955 | 0.74 | PREP (0.43) | CA12CA1CA9PREP | |
| SCHEMBL25353502 | 0.73 | GAA (0.42) | — | |
| SCHEMBL13534994 | 0.72 | CA12 (0.41) | CA12CA1CA9PREPALOX5AP | |
| SCHEMBL22581908 | 0.72 | CA12 (0.41) | CA12CA1CA9PREPALOX5AP | |
| SCHEMBL19924498 | 0.72 | ALOX5AP (0.43) | CA12CA1CA9PREPALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059198-A1 | BRM DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2025-02-20 | — | — | US | disclosed |
| EP-4436966-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-118679160-A | BRM targeting compounds and related methods of use | 阿维纳斯运营公司 | 2024-09-20 | — | — | CN | disclosed |
| WO-2023097031-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023097031-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059198-A1 | BRM DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, RBX1, BRAP | CA12 4350/4885CA1 4047/4885CA9 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.